News in brief: Cabozantinib a new treatment option in thyroid cancer; Oncologists’ views on exercise; Call for Medicare review of procedural specialist incomes

Cabozantinib shows promise as radioiodine-refractory DTC treatment Cabozantinib could offer a new treatment option for radioiodine-refractory differentiated thyroid cancer (DTC) patients who have no available standard of care. The tyrosine kinase inhibitor significantly prolonged progression-free survival over placebo (median not reached [96% CI: 5.7–not estimable NE] versus 1.9 months [1.8–3.6], HR: 0.22 [96% CI: 0.13–0.36, ...

Already a member?

Login to keep reading.

© 2022 the limbic